P
Portola Pharmaceuticals
Therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc. operated as a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments in thrombosis and other hematologic diseases. The company was established on September 2, 2003, by co-founders Charles J. Homcy, M.D., and David R. Philips. Homcy served as the company's president and CEO until 2010 before transitioning to the Board of Directors. The company's name was inspired by Gaspar de Portolà, the first European to see the San Francisco Bay. A significant milestone was its initial public offering (IPO) on NASDAQ in May 2013. In May 2020, Alexion Pharmaceuticals announced its intention to acquire Portola for $1.41 billion, a deal that was completed in July 2020.
The company's business model revolved around the research, development, and commercialization of novel drugs for patients with limited treatment options. Portola's revenue was generated through the sale of its approved products and through collaboration agreements with other pharmaceutical giants like Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo. These agreements often involved cash payments and development support, while Portola typically retained commercial rights. The company also entered into royalty agreements, such as a $150 million deal with HealthCare Royalty Partners for Andexxa, to secure non-dilutive funding for commercialization and further development.
Portola developed and brought to market two key products. The first, Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], is the first and only FDA-approved antidote for reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in patients experiencing life-threatening or uncontrolled bleeding. Approved by the FDA in May 2018 under an Accelerated Approval pathway, Andexxa addresses a critical need in emergency hospital settings. The second approved medicine, Bevyxxa (betrixaban), is an oral, once-daily Factor Xa inhibitor for preventing venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness. The company was also advancing cerdulatinib, a Syk/JAK inhibitor being investigated for the treatment of hematologic cancers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2013
- Employees
- 52
- Open positions
- None listed
- Dealroom signal
- 29.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Cardiology and cardiovascular, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2020 | $1.4B | $1.4B | Alexion Pharmaceuticals | ↗ |
| POST IPO EQUITYOther financing | Aug 2019 | $259M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Portola Pharmaceuticals is 210 monthly website visits, down 78.4% over the last three months. Portola Pharmaceuticals's team declined 46.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Portola Pharmaceuticals in the South San Francisco ecosystem
The Portola Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- PPProspect Venture Partners
Sutter Hill Ventures
MPM BioImpact
Frazier Healthcare Partners
Abingworth- AVAdvanced Technology Ventures
Alta Partners
Series B and later14 investors entered at this stage
Brookside Capital
AllianceBernstein
Ontario Teachers’ Pension Plan
Goldman Sachs
T. Rowe Price
D.E. Shaw Group
Janus Capital Group- PAPac-Link
- ICIBT Management Corporation
Adage Capital
Temasek
Eastern Capital
HealthCare Royalty
Athyrium Capital Management
Other known investors1 additional known investor
Alexion Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Portola Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Portola Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










